Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment

Because of the complexity of cancer, combination therapy is becoming increasingly important to overcome multidrug resistance in cancer and to enhance apoptosis. Cancer treatment using nanocarriers to co-deliver small interfering RNA (siRNA) and small molecule anticancer drugs has gained more attention because of its ability to generate synergistic anticancer effects via different mechanisms of action. This article provides a brief review on the recent developments of nanotechnology-based anticancer drug and/or siRNA delivery systems for cancer therapy. Particularly, the synergistic effects of combinatorial anticancer drug and siRNA therapy in various cancer models employing multifunctional drug/siRNA co-delivery nanocarriers have been discussed.

[1]  J. Inoue,et al.  NF‐κB activation in development and progression of cancer , 2007 .

[2]  Min Feng,et al.  Salt-induced stability and serum-resistance of polyglutamate polyelectrolyte brushes/nuclear factor-κB p65 siRNA Polyplex enhance the apoptosis and efficacy of doxorubicin. , 2013, Biomacromolecules.

[3]  R. Zhao,et al.  Engineering the Assemblies of Biomaterial Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor Efficacy , 2013, Advances in Materials.

[4]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family , 2012 .

[5]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[6]  W. Stein,et al.  Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. , 1997, Physiological reviews.

[7]  P. Slootweg,et al.  Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  V. Labhasetwar,et al.  Nanosystems in Drug Targeting: Opportunities and Challenges , 2005 .

[9]  Liangfang Zhang,et al.  Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. , 2012, Biochemical pharmacology.

[10]  Jing Zhao,et al.  Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. , 2013, Biomaterials.

[11]  E. Borden,et al.  Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis , 2004, Cell Death and Differentiation.

[12]  C. Bloch,et al.  Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. , 1994, Cancer research.

[13]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[14]  Dana Ravid,et al.  A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. , 2007, Cancer letters.

[15]  Saji George,et al.  Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. , 2009, ACS nano.

[16]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[17]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[18]  Qiao Jiang,et al.  Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. , 2010, ACS nano.

[19]  Jeong Yu Lee,et al.  Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA , 2013 .

[20]  Jayanth Panyam,et al.  Polymeric nanoparticles for siRNA delivery and gene silencing. , 2009, International journal of pharmaceutics.

[21]  P. Liu,et al.  Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. , 2013, Biomaterials.

[22]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[23]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[24]  N. Nishiyama,et al.  Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. , 2009, Biomacromolecules.

[25]  Soo Hyun Lee,et al.  PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[26]  H. Lage.  An overview of cancer multidrug resistance: a still unsolved problem , 2008, Cellular and Molecular Life Sciences.

[27]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[28]  H. J. Kim,et al.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.

[29]  W. Y. Seow,et al.  Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. , 2009, Biomacromolecules.

[30]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[31]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[32]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[33]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[34]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[35]  Ronit Satchi-Fainaro,et al.  Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. , 2013, Current opinion in biotechnology.

[36]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[37]  V. Yellepeddi,et al.  Recent trends in cancer drug resistance reversal strategies using nanoparticles , 2012, Expert opinion on drug delivery.

[38]  Achim Goepferich,et al.  Layer-by-layer assembled gold nanoparticles for siRNA delivery. , 2009, Nano letters.

[39]  D. Hallahan,et al.  Survivin as a therapeutic target for radiation sensitization in lung cancer. , 2004, Cancer research.

[40]  P. Couvreur,et al.  Nanocarriers’ entry into the cell: relevance to drug delivery , 2009, Cellular and Molecular Life Sciences.

[41]  Nicholas A Peppas,et al.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. , 2012, Nano today.

[42]  X. Shuai,et al.  Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. , 2012, Biomaterials.

[43]  Liang-Nian Ji,et al.  Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. , 2012, Biomaterials.

[44]  J. Nemunaitis,et al.  Small interfering RNA for experimental cancer therapy. , 2005, Current opinion in molecular therapeutics.

[45]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[46]  Zhuoxuan Lu,et al.  Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. , 2011, Small.

[47]  S. Fukuda,et al.  Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.

[48]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[49]  F. Caruso,et al.  Toward therapeutic delivery with layer-by-layer engineered particles. , 2011, ACS nano.

[50]  Anjan Nan,et al.  Combination Drug Delivery Approaches in Metastatic Breast Cancer , 2012, Journal of drug delivery.

[51]  N. M. Zaki,et al.  Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting , 2010, Expert opinion on drug delivery.

[52]  Mansoor M. Amiji,et al.  Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells , 2009, Cancer Chemotherapy and Pharmacology.

[53]  Ki-Bum Lee,et al.  Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. , 2011, Molecular pharmaceutics.

[54]  A. Lavasanifar,et al.  Recent attempts at RNAi‐mediated P‐glycoprotein downregulation for reversal of multidrug resistance in cancer , 2013, Medicinal research reviews.

[55]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[56]  M. Saraswathy,et al.  Different strategies to overcome multidrug resistance in cancer. , 2013, Biotechnology advances.

[57]  H. Chung,et al.  Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[58]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[59]  M. Breunig,et al.  Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[60]  Hua Ai,et al.  The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. , 2011, Biomaterials.

[61]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[62]  H. Uludaǧ,et al.  Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells , 2013, Cancer Gene Therapy.

[63]  Liping Xie,et al.  Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells , 2013, World Journal of Surgical Oncology.

[64]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[65]  G. Devi,et al.  siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.

[66]  T. Minko,et al.  Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[67]  A. D. Fougerolles.  Delivery vehicles for small interfering RNA in vivo. , 2008 .

[68]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[69]  Chandana Mohanty,et al.  Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. , 2012, Drug discovery today.

[70]  Bai Xiang,et al.  pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. , 2013, Biomaterials.

[71]  T. Rana,et al.  Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.

[72]  Robert Langer,et al.  Targeted nanoparticles for cancer therapy , 2007 .

[73]  T. Park,et al.  LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. , 2008, Bioconjugate chemistry.

[74]  A. R. Kulkarni,et al.  Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review , 2011, Expert opinion on drug delivery.

[75]  Kam W Leong,et al.  Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. , 2011, ACS nano.

[76]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[77]  V. Torchilin,et al.  P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. , 2012, Nanomedicine.

[78]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[79]  Y. Won,et al.  Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Afsaneh Lavasanifar,et al.  Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. , 2011, ACS nano.

[81]  H. Uludaǧ,et al.  Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. , 2009, Biomaterials.

[82]  Wenjin Xu,et al.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. , 2012, Nanoscale.

[83]  Jianqing Gao,et al.  Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[84]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[85]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[86]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[87]  J. Feijen,et al.  Reducible poly(amido ethylenimine) directed to enhance RNA interference. , 2007, Biomaterials.

[88]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[89]  Huixin He,et al.  Nanocarriers for the simultaneous co-delivery of therapeutic genes and anticancer drugs. , 2012, Current pharmaceutical biotechnology.

[90]  Mark E. Davis,et al.  Non-viral gene delivery systems. , 2002, Current opinion in biotechnology.

[91]  Jun Wang,et al.  Polymeric‐Micelle‐Based Nanomedicine for siRNA Delivery , 2013 .